NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and ...

NATICK, Mass. and MIAMI, Jan. 16, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for ...

Boston Scientific Corp. has announced it has received FDA approval and market launch of its Epic vascular self-expanding stent system, according to a news release. Boston Scientific said the Epic ...

"The Epic Stent is a novel stent platform designed to offer both acute and clinical advantages over older-generation stent systems," said Jeff Mirviss, president of the company's peripheral ...

Earlier this year, Boston Scientific had announced that the Orion trial met its primary clinical endpoint. The Epic vascular stent recorded only 3.4% of major adverse events in the nine-month period ...

NATICK, Mass., Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol ...

NATICK, Mass., May 17, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding Stent ...

This is the third new peripheral balloon catheter launched in 2011. Earlier launches include Mustang percutaneous transluminal angioplasty balloon (June 2011) and the Coyote balloon catheter ...

According to Report Ocean latest Research Report “Vascular Stent Market ” Size, Share, Growth, Trends, Market research, Market analysis, outlook period 2023 to 2031 (Drivers, Constraints, ...

Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting NATICK, Mass. -- Boston Scientific Corporation reports twelve-month clinical endpoint data from the ...

The Epic Stent demonstrated a low nine-month MAE rate of 3.4 percent in the intent-to-treat population, which was significantly lower than the pre-specified performance goal of 17 percent (p<0.001) ...

Boston Scientific 's ( BSX) focus on portfolio expansion is yielding results with several product approvals. Recently, the company received approval from the US Food and Drug Administration (FDA) for ...